ICON PLC (ICLR) - Total Liabilities

Latest as of June 2026: $7.02 Billion USD

Based on the latest financial reports, ICON PLC (ICLR) has total liabilities worth $7.02 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ICON PLC (ICLR) long-term investment share to see how much of total assets are deployed in long-term investments.

ICON PLC - Total Liabilities Trend (1998–2025)

This chart illustrates how ICON PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ICON PLC assets under control.

ICON PLC Competitors by Total Liabilities

The table below lists competitors of ICON PLC ranked by their total liabilities.

Company Country Total Liabilities
LTIMindtree Limited
NSE:LTM
India Rs130.88 Billion
Lingyi iTech Guangdong Co
SHE:002600
China CN¥31.34 Billion
Assurant, Inc.
NYSE:AIZ
USA $29.98 Billion
Taiwan Cooperative Financial Holding Co Ltd
TW:5880
Taiwan NT$5.01 Trillion
COSCO Shipping Energy Transportation Co Ltd
SHG:600026
China CN¥42.43 Billion
Neurocrine Biosciences Inc
NASDAQ:NBIX
USA $1.38 Billion
Yunnan Baiyao Group Co Ltd
SHE:000538
China CN¥13.53 Billion

Liability Composition Analysis (1998–2025)

This chart breaks down ICON PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of ICON PLC to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.75 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ICON PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ICON PLC (1998–2025)

The table below shows the annual total liabilities of ICON PLC from 1998 to 2025.

Year Total Liabilities Change
2025-12-31 $7.08 Billion -3.78%
2024-12-31 $7.35 Billion -5.09%
2023-12-31 $7.75 Billion -10.80%
2022-12-31 $8.69 Billion -6.79%
2021-12-31 $9.32 Billion +487.89%
2020-12-31 $1.59 Billion +22.95%
2019-12-31 $1.29 Billion +28.95%
2018-12-31 $999.97 Million +4.64%
2017-12-31 $955.62 Million +8.51%
2016-12-31 $880.67 Million -7.76%
2015-12-31 $954.71 Million +65.29%
2014-12-31 $577.59 Million +8.59%
2013-12-31 $531.88 Million +18.85%
2012-12-31 $447.53 Million +26.45%
2011-12-31 $353.92 Million +26.61%
2010-12-31 $279.54 Million -16.84%
2009-12-31 $336.15 Million -18.20%
2008-12-31 $410.92 Million +35.42%
2007-12-31 $303.43 Million +75.92%
2006-12-31 $172.48 Million +61.78%
2005-12-31 $106.61 Million -10.08%
2004-12-31 $118.56 Million +73.19%
2003-12-31 $68.46 Million -30.22%
2002-12-31 $98.10 Million +88.76%
2001-12-31 $51.97 Million +67.49%
2000-12-31 $31.03 Million +34.53%
1999-12-31 $23.07 Million -1.85%
1998-12-31 $23.50 Million --

About ICON PLC

NASDAQ:ICLR USA Diagnostics & Research
Market Cap
$13.30 Billion
Market Cap Rank
#1816 Global
#687 in USA
Share Price
$172.33
Change (1 day)
-0.90%
52-Week Range
$80.08 - $202.92
All Time High
$346.20
About

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It… Read more